12th May 2025 Curium receives marketing authorization in Switzerland for PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
10th April 2025 Curium enhances its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis